Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 5, 1996, Pages 402-405

  Denton, M ^a,b   Todd, N J ^a   Littlewood, J M ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CIPROFLOXACIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0029897478     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01690098     Document Type: Article

References (12)

1. Ballestero S, Virseda I, Escobar H, Suarez L, Baquero F: Stenotrophomonas maltophilia in cystic fibrosis patients. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 728-729.
2. Chatelut M, Dournes JL, Chabanon G, Marty N: Epidemiological typing of Stenotrophomonas (Xanthomonas) maltophilia by PCR. Journal of Clinical Microbiology 1995, 33: 912-914.
3. Hoiby N: Pseudomonas infection in cystic fibrosis. In: Dodge JA, Brock DJH, Widdicombe JH (ed): Cystic fibrosis - current topics: volume 1, Wiley, Chichester, UK, 1993, p. 251-268.
4. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH: Nebulised colomycin for early Pseudomonas aeruginosa colonisation in cystic fibrosis. Lancet 1985, i: 865.
5. Valerius NH, Koch C, Hoiby N: Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338: 725-726.
6. Jensen T, Pedersen SS, Hoiby N, Koch C, Flensborg EW: Use of antibiotics in cystic fibrosis. The Danish approach. Antibiotics and Chemotherapy 1989, 42: 237-246.
7. Khardori N, Elting L, Wong E, Schable B, Bodey GP: Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Reviews of Infectious Diseases 1990, 12: 997-1003.
8. Lesco-Bornet M, Pierre J, Sarkis-Karam D, Lubera S, Bergogne-Berezin E: Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrobial Agents and Chemotherapy 1992, 36: 669-671.
9. Spencer RC: The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. Journal of Hospital Infection 1995, 30, Supplement: 453-464.
10. Vazquez C, Municio M, Corera M, Gaztelurrutia L, Sojo A, Vitoria JC: Early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Acta Paediatrica 1993, 82: 308-309.
11. Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, Kaufmann ME, Pitt TL: Home-use nebulisers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. Journal of Clinical Microbiology 1996, 34: 584-587.
12. Gladman G, Connor PJ, Williams RF, David TJ: Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Archives of Disease in Childhood 1992, 67: 192-195.